NCT05537571COMPLETEDanonymous

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Sponsor

Source record

Silence Therapeutics plc

Phase

Source record

PHASE2

Modality

AI-normalized

RNA therapy

Target

AI-normalized

SLN360, Placebo

Indication / condition

AI-normalized

Cardiovascular Diseases

Intervention

Source record

SLN360, Placebo

Related intelligence directories

Indication directory: Cardiovascular Diseases Modality directory: RNA therapy Target directory: SLN360

Source & freshness

Source record

NCT ID

NCT05537571

Original source

ClinicalTrials.gov

Source last updated

Jul 01, 2025

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05537571

Title

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Sponsor

Silence Therapeutics plc

Status

COMPLETED

Phase

PHASE2

Condition raw

Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)

Condition normalized

Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)

Modality raw

RNA therapy

Modality normalized

RNA therapy

Target raw

SLN360, Placebo

Target normalized

SLN360, Placebo

Interventions

SLN360, Placebo

Public preview

Source record

Phase 2 study to evaluate the efficacy, safety and tolerability of SLN360 administered subcutaneously (SC) compared with placebo in adult participants with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT05537571

Status

COMPLETED

Phase

PHASE2

Sponsor

Silence Therapeutics plc

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJul 01, 2025

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05537571

Indication

Cardiovascular Diseases

Modality

RNA therapy

Target

SLN360, Placebo

Intervention

SLN360, Placebo

Source record